GSK stock gains Japan orphan status for velzatinib in GIST
Published on 11/20/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline milestone strengthens oncology focus
- Japan granted orphan drug designation to velzatinib for gastrointestinal stromal tumour.
- GSK is running phase III studies in first- and second-line advanced or metastatic GIST.
- Second-line trial enrolment is ahead of schedule, with data expected in the second half of 2027.
GSK said on Thursday, November 19, that Japan's Ministry of Health, Labour and Welfare granted orphan drug designation to velzatinib for gastrointestinal stromal tumour, adding a regulatory milestone to the drugmaker's oncology pipeline. The company announced the decision in a GSK press release.
Velzatinib is a selective KIT inhibitor being developed for advanced gastrointestinal stromal tumour, a rare cancer that commonly arises in the stomach or small intestine. GSK said the Japanese designation was supported by results from the ongoing phase I/Ib StrateGIST 1 trial, which showed promising anti-tumour activity and a promising tolerability profile.
Development moves into late-stage trials
The designation adds to US Food and Drug Administration Fast Track status and orphan drug designations in the United States and European Union. GSK said phase III studies are under way in first- and second-line advanced or metastatic GIST, broadening the potential development path beyond patients who have already received several treatments.
Enrollment in the second-line study is tracking ahead of schedule, according to the company. GSK expects data from that trial in the second half of 2027. A separate phase II study in Japan is evaluating velzatinib in patients whose disease has progressed or who cannot tolerate available treatment options.
Seven velzatinib abstracts are scheduled for presentation at the Connective Tissue Oncology Society annual meeting in Seoul from November 18 through November 21. The presentations cover clinical analyses by KIT mutation and treatment line, as well as preclinical work on mutation coverage and translational biomarkers.
Oncology pipeline remains in focus
The Japanese designation supports development in a market with a high incidence of GIST, but it is not a marketing authorization. Commercial prospects remain tied to the outcome of the ongoing phase III studies and the company's ability to establish activity across relevant KIT mutations while maintaining tolerability.
GSK stock traded at 22.10 euros on Lang & Schwarz at 11:36 CET on Friday, November 20, 2026.
GSK plc
- Company: GSK plc
- ISIN: GB00BN7SWP63
- Trading venue: Lang & Schwarz
- Quoted price: 22.10 euros at 11:36 CET on Friday, November 20, 2026
- Velzatinib milestone: Japan orphan drug designation for gastrointestinal stromal tumour on November 19, 2026
GSK's primary listing is in the United Kingdom, where the FTSE 100 provides the relevant market context.
